Previous 10 | Next 10 |
Panbela Therapeutics ([[PBLA]]) is set to be added to Russell Microcap Index at the conclusion of the Russell US Indexes annual reconstitution, effective opening of the equity markets on June 28.“We look forward to the opportunity to communicate our strate...
MINNEAPOLIS, June 08, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, is set to join the Russell Microcap® Index at the conclusion of the 202...
Purple Biotech (PPBT) -10%.ShiftPixy (PIXY) -9%.MoneyGram International MGI -7% after announces $100M at-the-market equity offering programPanbela Therapeutics (PBLA) -6%.Fuel Tech (FTEK) -6%.BK Technologies BKTI -6% after secures $11.1M capital via equity raise. For fur...
MINNEAPOLIS, June 04, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced the presentation of interim clinical data from its Phase 1b ...
MINNEAPOLIS, May 26, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that Company founder, Michael T. Cullen, MD, MBA, retired ...
Panbela Therapeutics Inc. (PBLA) Q1 2021 Earnings Conference Call May 12, 2021 4:30 PM ET Company Participants James Carbonara - Hayden IR Jennifer Simpson - President and Chief Executive Officer Susan Horvath - Vice President and Chief Financial Officer Conference Call Participants Robin Gar...
Panbela Therapeutics (PBLA): Q1 GAAP EPS of -$0.23.Total cash of $8.1M.Press Release For further details see: Panbela Therapeutics reports Q1 results
MINNEAPOLIS, May 12, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today provides a business update and reports financial results for the quarte...
MINNEAPOLIS, April 28, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that it will host a conference call on May 12, 2021 at 4:30 ...
Panbela Therapeutics (PBLA) announces that the U.S. FDA has lifted the partial clinical hold on the company's Phase 1 first-line study of SBP-101 when used in combination with standard of care agents gemcitabine and nab-paclitaxel for treatment of patients with metastatic pancreatic duct...
News, Short Squeeze, Breakout and More Instantly...
Panbela Therapeutics Inc Com Company Name:
PBLA Stock Symbol:
NASDAQ Market:
Panbela Therapeutics Inc Com Website:
DSMB Recommends Continuation without Modification for Third Time Safety Review Included 395 Patients Interim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate Low Event Rate Suggests Potential for Prolonged Survival Rapid Enrollment P...
MINNEAPOLIS, June 10, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announces an oral presentation at the Digestive Disease Week (DDW) conference,...
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the q...